Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 5/20 | 0.47 |
| ▸ | DRD5 | P21918 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991420 | 1.00 | MAOA (0.55) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL6883015 | 0.94 | MAOA (0.59) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL160943 | 0.92 | HTR2A (0.55) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL2056191 | 0.85 | POLB (0.43) | MAOAMAOBSLC6A4DRD3HTR2A | |
| SCHEMBL29991500 | 0.85 | POLB (0.43) | MAOAMAOBSLC6A4DRD3HTR2A | |
| SCHEMBL4323033 | 0.80 | DRD1 (0.72) | MAOAMAOBSLC6A4DRD1DRD5 | |
| SCHEMBL29598312 | 0.80 | DRD1 (0.72) | MAOAMAOBSLC6A4DRD1DRD5 | |
| Nitric Acid SCHEMBL165780 | 0.79 | HTR2A (0.50) | DRD1DRD5DRD2DRD3HTR2A | |
| SCHEMBL15649743 | 0.79 | MET (0.42) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL12836477 | 0.78 | HTR2A (0.46) | DRD2HTR2AHTR2CHTR2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586589-B2 | Piperidine and piperazine phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2009125870-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | MAOA 885/4885MAOB 1062/4885SLC6A4 351/4885 |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | MAOA 2275/4885MAOB 2370/4885SLC6A4 271/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | MAOA 746/4885MAOB 117/4885SLC6A4 65/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | MAOA 746/4885MAOB 117/4885SLC6A4 65/4885 |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | MAOA 2557/4885MAOB 2012/4885SLC6A4 4575/4885 |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | KCNJ2, KCNJ1, KCNJ11 | MAOA 2491/4885MAOB 1834/4885SLC6A4 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.